



Making Lives Safer Through

# NANOTECHNOLOGY

KEEPING SURFACES CLEAN

CORPORATE DECK

CSE: FNDX | OTCQB: FDXTF | FSE: E8D

JANUARY 2024



# Forward-Looking Statement

This presentation contains certain forward-looking statements within the meaning of Canadian securities legislation, including with respect to: the plans of the Company; expectations regarding industry trends, including with respect to the antimicrobial surface and coating market, overall market growth rates and the Company's growth rates and growth strategies; that microbe repellent technology is a promising, high-growth industry; the use of available funds; the performance of the Company's business and operations; the Company's expectations regarding revenues, expenses and anticipated cash needs; the intention to grow the Company's business, product pipeline and operations; the expected timing and completion of the Company's near-term objectives; the expected timing and achievement of commercial launch of REPELWRAP™ film in 2H2024 and for other products; laws and regulations and any amendments thereto applicable to the Company; the Company's competitive advantages and business and growth strategies; the Company's future product offerings, including potential new applications (i.e. catheters) and new formulations (i.e. spray); the Company's research and development initiatives and expected results thereof; the Company's growing patent portfolio; the Company entering into distribution, manufacturing and other business relationships, in Canada, the United States, and globally; the potential of the Company's technology to protect against the spread of pathogens on surfaces through repelling bacteria and viruses that come in contact with its surface; that the Company's technology will bring significant value in controlling the spread of surface borne infectious diseases; trends regarding healthcare-acquired infections; the Company's ability to access multi-million-dollar markets; proprietary REPELWRAP™ film and/or spray could be used on high-touch surfaces such as bed rails, doorknobs, and medical devices to help prevent pathogen transmission; the Company's nanotechnology has the potential to be applied to other types of surfaces and materials – such as catheters which could significantly help reduce blockages caused by bacterial colony and/or blood clot formation in long-use catheters and that underserved markets like this offer potentially future upside, if the Company can successfully adapt their technology; the Company's intention to initially target REPELWRAP™ film towards healthcare settings and high traffic public touchpoints; that as the Company continues its product development, we may see it used to protect surfaces in other high traffic places like the transportation, education, sports and entertainment sectors; the growing global commitment to reduce the spread of pathogens; the development of the Company's spray nanotechnology, which could be easier to apply to many surfaces and expand potential market applications; the Company's organic growth strategy and expansion strategy; line extensions for REPELWRAP™ film; development of a nano-coating for catheters and further development of core technology as well as into additional applications; expansion into vertical markets; licensing of additional nanotechnology formulations and/or complementary products that reduce pathogen spread; potential licensing, M&A and partnerships within the infectious disease space; and that REPELWRAP™ film and/or spray will provide additional protection to current disinfecting practices to control the spread of pathogens.

Important factors that could cause future results to differ materially from those anticipated in these forward-looking statements include: product candidates only being in formulation/reformulation stages; limited operating history, no revenues and uncertainty around additional financing; negative cash flow history; no production history and lack of revenues from sales; no history of manufacturing or distribution; highly competitive industry; satisfying the terms of the License Agreement, Spray License Agreement and Collaborative Research Agreements between the Company and McMaster University and maintaining licenses in good standing; inability of McMaster University to satisfy the terms under the License Agreement, Spray License Agreement and Collaborative Research Agreements; ability to successfully complete scale-up and development of commercial film, spray or other products; research and development activities; reliance on grant funding; limited number of products; dependence on collaborative partners, licensors and others; no formal manufacturing or distribution agreements in place; changes and restrictions due to legal and regulatory requirements; dependence on each product's acceptance in the market; possibility of smaller market opportunities than anticipated; increasing regulatory and compliance costs for public companies; global economic instability; product liability claims and lawsuits; system failures; reliance on management and loss of key employees or inability to hire key personnel; limited experience of senior management in managing a public company; fraudulent or illegal activity by employees, contractors and consultants; inability to effect service of process on some of the Company's directors and officers; management's efforts and abilities; potential conflicts of interest; inability to protect intellectual property rights; inability to secure patents or grow its patent portfolio; infringement on proprietary rights of third parties; risks related to forward-looking information; volatility of the market price of the Company's common shares; potential dilution of the common shares; lack of an active, liquid and orderly trading market for the common shares; failure of securities or industry analysts to publish research or publish inaccurate or unfavorable research about the Company; inability or unwillingness to pay dividends; exchange rate fluctuations between the Canadian dollar and the U.S. dollar; effect of COVID-19 public health crisis or another global health pandemic; use of available funds; effect of general economic and political conditions; internal controls; and other risk factors set forth in the Company's public filings, publicly available through the Canadian Securities Administrators' System for Electronic Document Analysis and Retrieval (SEDAR) at [www.sedarplus.ca](http://www.sedarplus.ca). The reader is urged to refer to the Company's most recently filed MD&A and other filings, publicly available through SEDAR+ at [www.sedarplus.ca](http://www.sedarplus.ca) for a more complete discussion of such risk factors and their potential effects. Except to the extent required by applicable securities laws and the policies of the Canadian Securities Exchange, the Company undertakes no obligation to update these forward-looking statements if management's beliefs, estimates or opinions, or other factors, should change. New factors emerge from time to time, and it is not possible for the Company to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any Forward-looking statements contained in this presentation are expressly qualified in their entirety by this cautionary statement.

While the information contained in this presentation is believed to be accurate, the Company expressly disclaims any and all liability for any losses, claims or damages of whatsoever kind based upon the information contained in, or omissions from, this presentation or any oral communication transmitted in connection therewith. In addition, none of the statements contained in this presentation are intended to be, nor shall be deemed to be, representations or warranties of the Company. Where the information is from third-party sources, the information is from sources believed to be reliable, but the Company has not independently verified any of such information contained herein.

This presentation is not, and under no circumstances is to be construed as, a prospectus, an offering memorandum, an advertisement or a public offering of securities. Under no circumstances should the information contained herein be considered an offer to sell or a solicitation of an offer to buy any securities.

# Developing novel protective nano-coatings to keep surfaces clean



## Unique Disruptive Nanotechnology

Award-winning, patent pending nanotechnology with instant repelling properties against bacteria, viruses, blood and liquids



## Global Need to Keep Surfaces Clean

Several surfaces in healthcare and other venues are prone to contamination and can lead to serious and potentially lethal infections



## Accelerating Development

Lead product, REPELWRAP™ film, in scale-up development to protect high touch surfaces from contamination



## Share Structure

As at December 31, 2023, 53.28 million shares issued, 75.8 million fully diluted. 23.5 million shares currently subject to voluntary pooling/escrow.



## Potential to Access Multi-Million-Dollar Markets

Focus on protecting high-touch surfaces (i.e., healthcare, transportation, entertainment & schools) and medical devices including catheters



## Strong Leadership

Experienced management team, Board of Directors with extensive expertise in growing & leading businesses, R&D, product launches, finance, capital markets



## Platform Nanotechnology

Multiple nano-coatings in development, including film, spray formulation and catheter coating

# Keeping Surfaces Clean Requires Innovative Solutions

## Problem

- High-touch surfaces and catheters are potential sources of contamination that can lead to healthcare-associated infections
- Healthcare-associated infections are one of the top 10 frequent causes of death in the U.S.<sup>1,2</sup>
- > 98,000 of deaths annually in U.S.<sup>2</sup>
- US\$28.4 billion in direct medical costs annually in the U.S.<sup>3</sup>

### Sources:

1. Future Markets Technology Report, Advanced Microbial Coatings, 2023
2. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245375/>
3. <https://www.cdc.gov/policy/polaris/healthtopics/hai/index.html>

## Solution


- FendX is developing nano-coating products to protect high-touch surfaces and catheters from contamination
- Data collected at McMaster University demonstrates instant and 24/7 reduction in adherence of bacteria, viruses, blood and other liquids<sup>4,5,7</sup>
- Significantly reduces transmission of bacteria and viruses on high-touch surfaces<sup>4,5,6</sup>

### Sources:


4. <https://pubs.acs.org/doi/10.1021/acsami.1c21476?ref=pdf>
5. <https://pubs.acs.org/doi/10.1021/acsami.3c11074>
6. <https://pubs.acs.org/doi/10.1021/acsami.2c23119?ref=pdf>
7. <https://onlinelibrary.wiley.com/doi/abs/10.1002/sml.202108112>

# Product Pipeline

Developing film and spray coatings to reduce the spread of bacteria and viruses on high-touch surfaces prone to contamination



Developing nano-coating to protect medical catheters from bacterial infections and/or blood clots




# Protecting High-Touch Surfaces Prone to Contamination

## How Our Nano-Coating Works

- When a contaminated hand touches a nano-coated surface, the contamination tends to stay on the hand and not transfer to the surface<sup>1,2,3</sup>

Sources:

- <https://pubs.acs.org/doi/10.1021/acsami.1c21476?ref=pdf>
- <https://pubs.acs.org/doi/10.1021/acsami.3c11074>
- <https://pubs.acs.org/doi/10.1021/acsami.2c23119?ref=pdf>



Schematic illustration comparing transfer of viruses from common high-touch surfaces from a contaminated hand.


# REPELWRAP™ Film

## Lead Product in Development to Protect High Touch Surfaces Prone to Contamination

- Provides immediate, 24/7 protection for extended periods of time
- Being developed for easy application to flat surfaces, handrails etc.
- Effective repelling rates:
  - >99% reduction in adhesion of a Covid-19 like virus<sup>1</sup>
  - >98% reduction in adhesion of E. coli, B. subtilis and MRSA<sup>2</sup>

Sources:

1. <https://pubs.acs.org/doi/10.1021/acsami.1c21476?ref=pdf>
2. <https://pubs.acs.org/doi/10.1021/acsami.3c11074>




Schematic illustration demonstrating how REPELWRAP™ film is applied.

# REPELWRAP™ Film

## Film Composition in Scale-up Development

- Involves deposition of nanoparticles and fluoropolymers on plastic film and then thermally shrunk
- Creates an inert surface with unique repelling properties that prevents the adhesion of bacteria, viruses, blood and other liquids



Schematic diagram illustrating process of making REPELWRAP™ film.




# REPELWRAP™ Film

## Currently in Scale-Up Development and Pilot Manufacturing Runs With Dunmore\*

- Production time streamlined
- Achieved the expected repelling properties
- In the process of optimizing formulation and manufacturing process
- Anticipate introduction of a commercial product in 2H2024

\* Dunmore International Corp. (“Dunmore”), a Steel Partners Holdings L.P. (NYSE:SPLP) operating company is a globally recognized film manufacturer.




Schematic illustration of manufacturing process.

# REPELWRAP™ Spray

## In Development to Protect High Touch Surfaces Prone to Contamination:

- Expected to be easier to apply providing immediate and 24/7 protection for extended periods of time and expand applications
- Both repels and kills:
  - **>98%** reduction in adhesion of MRSA and Covid-19 like virus<sup>1</sup>
  - **99.98%** reduction in biofilm formation for both MRSA and P. aeruginosa – killing effectiveness<sup>1</sup>

1. <https://pubs.acs.org/doi/10.1021/acsami.2c23119?ref=pdf>



In intermediate scale-up development with manufacturing partner, nanoComposix LLC, a Fortis Life Science Company

# REPELWRAP™ Film and Spray Competitive Landscape

	REPELWRAP™ Film <sup>1</sup>	Liquid Disinfectants	Metal-Containing* and Photo-Activated Films**
Surface repels bacteria, viruses, blood and liquids	+++	-	-
Instantly effective	+++	+++	+
24/7 protection	+++	-	+++
Does not promote bacterial resistance	+++	+	+

\* Silver and copper containing films; key companies include Coptek, NeverGerms, SAFEHandles, Silver Defender

\*\*Key companies include FN-NANO, Kastus, NanoSeptic

<sup>1</sup> Based on McMaster testing of REPELWRAP™ film lab prototype (ACS Appl. Mater. Interfaces 2022, 14, 11068-11077; ACS Nano. 2020 Jan 28, 14 (1) 454-465; 3)

# Developing Nano-Coating for Catheters to Reduce Bacterial Infections and Blood Clot Formation

## Findings from early-stage research of our nanotechnology that is lubricant infused<sup>1</sup>:

- Lubricant infused nano-surface provides significant reduction in bacterial and blood adhesion under dynamic flow conditions
  - 96.5% reduction in bacterial attachment of E. coli after 48 hours of flow exposure
  - 95.8% reduction in blood or fibrin networks after 24 hours of flow exposure to whole blood

## Estimated annual infection cases and cost of common catheter complications in U.S.

	Annual Cases	Medical Cost Estimates
Foley catheter-associate infections	~1 million <sup>2</sup>	~\$0.15-1.82 billion <sup>2</sup>
CVC*-associated blood clots and infections	~80,000 <sup>3</sup>	\$0.3 – 2.3 billion <sup>3</sup>

\*CVC – central venous catheters

### Sources:

1. <https://onlinelibrary.wiley.com/doi/abs/10.1002/sml.202108112>
2. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992741/>
3. <https://www.infectioncontroltoday.com/view/new-iv-guidelines-whats-most-critical-know>

# Building A Robust Patent Portfolio

## Protecting Licensed Nanotechnology Used to Develop Film, Spray and Catheter Coatings

### Family 1 - Film Coating:

- Canada Patent Application Number 3142127, entitled OMNIPHOBIC SURFACES WITH HIERARCHICAL STRUCTURES, AND METHODS OF MAKING AND USES THEREOF
- European Patent Application Number EP20819372.2, entitled OMNIPHOBIC SURFACES WITH HIERARCHICAL STRUCTURES, AND METHODS OF MAKING AND USES THEREOF
- Japan Patent Application Number 2021-572059, entitled OMNIPHOBIC SURFACES WITH HIERARCHICAL STRUCTURES, AND METHODS OF MAKING AND USES THEREOF
- PCT Patent Application Number PCT/CA2020/050766, entitled OMNIPHOBIC SURFACES WITH HIERARCHICAL STRUCTURES, AND METHODS OF MAKING AND USES THEREOF
- US Patent Application Number 62/856392, entitled OMNIPHOBIC SURFACES WITH HIERARCHICAL STRUCTURES, AND METHODS OF MAKING AND USES THEREOF
- US Patent Application Number 17/616,374, entitled OMNIPHOBIC SURFACES WITH HIERARCHICAL STRUCTURES, AND METHODS OF MAKING AND USES THEREOF
- Hong Kong Patent Application Number 62022061224.1, entitled OMNIPHOBIC SURFACES WITH HIERARCHICAL STRUCTURES, AND METHODS OF MAKING AND USES THEREOF
- Chinese Patent Number ZL 202080055337.6 entitled OMNIPHOBIC SURFACES WITH HIERARCHICAL STRUCTURES, AND METHODS OF MAKING AND USES THEREOF

### Family 2 – Spray Coating:

- US Provisional Patent Application No 63/415078, entitled OMNIPHOBIC ANTIMICROBIAL MICROPARTICLES AND COMPOSITIONS THEREOF

### Family 3 – Formulation in Development to Coat Catheters:


- US Patent Application Number 63/260372, entitled METHODS OF MAKING OMNIPHOBIC MATERIALS WITH HIERARCHICAL STRUCTURES AND USES THEREOF
- PCT Patent Application Number PCT/CA2022/051259, entitled METHODS OF MAKING OMNIPHOBIC MATERIALS WITH HIERARCHICAL STRUCTURES AND USES THEREOF

### Family 4 – Non-fluoropolymer Coating:

- US Patent Application Number 63/260371, entitled FLUORINE-FREE SUPERHYDROPHOBIC SURFACES, METHODS OF MAKING AND USES THEREOF
- PCT Patent Application Number PCT/CA2022/051249, entitled FLUORINE-FREE SUPERHYDROPHOBIC SURFACES, METHODS OF MAKING AND USES THEREOF


# Antimicrobial & Antiviral Nano-Coating Market Offers Significant Opportunity

Global market estimated to reach US\$1.3 billion in 2026<sup>1</sup>



1. Future Markets Technology Report, Advanced Microbial Coatings, 2021

# Partnership Strategy with Manufacturers and Distributors



## Manufacturers

Plan to establish partnerships to manufacture REPELWRAP™ film and other products for distribution in Canada, U.S. and other global markets



## Sales Distributors

Plan to secure partnerships to sell REPELWRAP™ film in Canada, U.S. and other global markets

Goal is to sell in several high-touch markets with distributors with a broad customer base and high call frequency



## Growth Strategy

- Explore additional uses of nanotechnology
- Assess licensing/acquisition opportunities to expand product pipeline and intellectual property portfolio
- Initial REPELWRAP™ film product launch in Canada estimated 2H2024, with expansion into the U.S. and other markets



# Proven Management Team




**Dr. Carolyn Myers MBA, PhD**  
President, CEO & Director

- Principal of BioEnsemble LLC, assisting start-ups and small pharma companies in developing their business strategy and planning
- Vice President International Business Development and Alliance Management at Allergan PLC (market cap \$83 Bn, 2017, now Abbvie),
- President of Dey Laboratories and President of Mylan Technologies Inc. (market cap \$9.2 Bn, 2011, now Viatris Inc.)
- Senior management at Pharmacia Corporation (now Pfizer)
- Director Hyloris Pharmaceuticals SA (BR:HYL), EyeD Pharma (private)



**Andrea Mulder BPHE, MBA**  
COO

- Over 25 years of pharma/biotech expertise in marketing and sales leadership
- Led the launches of over 10 pharmaceutical products in Canada
- Significant therapeutic knowledge in infectious disease, immunology, neurology, respiratory and oncology
- Member of Global and/or Canadian leadership teams at: Eisai, Ipsen, Pfizer, GlaxoSmithKline, Roche and Johnson and Johnson



**Rose Zanic CPA, CA**  
CFO & Corporate Secretary

- Over 25 years of capital markets and corporate finance expertise
- Significant experience advising Canadian public companies with financing, M&A transactions and providing public company administration.
- Previously Senior Vice-President, Corporate Finance at Wolverton Securities Ltd.
- Experience as a director and/or officer with several Canadian publicly listed companies
- Member of the TSX Venture Exchange BC Local Advisory Committee

# Board of Directors

## Dr. Carolyn Myers MBA, PhD

### President, CEO & Director

- Principal of BioEnsemble LLC, assisting start-ups and small pharma companies in developing their business strategy and planning
- Vice President International Business Development and Alliance Management at Allergan PLC (market cap \$83 Bn, 2017, now Abbvie),
- President of Dey Laboratories and President of Mylan Technologies Inc. (market cap \$9.2 Bn, 2011, now Viatris Inc.)
- Senior management at Pharmacia Corporation (now Pfizer)
- Director Hyloris Pharmaceuticals SA (BR:HYL), EyeD Pharma (private)

## Stephen Randall CPA, CGA

### Independent Board Member & Audit Committee Chair

- Senior financial manager and Director with over 40 years' experience.
- Served in senior financial roles with both private, publicly traded and start-up companies in the manufacturing, telecommunications, technology, and medical device sectors.
- Former Board Member, CFO and Corporate Secretary of Titan Medical Inc (TSX: TMD and NASDAQ: TMDI)

## Pierre Soulard B.C.L., LLB, LLM

### Independent Board Member

- Former Chief Legal Officer of CoinSmart (NEO: SMRT)
- Former partner, at Miller Thomson, a leading Canadian law firm.
- Focused on securities law, corporate finance, mergers and acquisitions and corporate governance for a wide range of national and international issuers and investors.

# Share Structure

CSE: FNDX / AS OF DECEMBER 31, 2023

Common Stock <sup>1</sup>	<b>53,284,893</b>
Stock Options	<b>2,741,667</b>
Warrants	<b>15,612,520</b>
Bonus Shares <sup>2</sup>	<b>4,150,000</b>
Fully-Diluted	<b>75,789,080</b>

- Efficient capital structure
- Over 46%<sup>1</sup> of outstanding common shares subject to escrow/pooling restrictions

<sup>1</sup> 24,725,401 shares subject to escrow/voluntary pooling restrictions as at December 31, 2023.

<sup>2</sup> Shares issuable upon satisfaction of certain development milestones.

# Thank You!

Reach out to us with any questions.

[investor@fendxtech.com](mailto:investor@fendxtech.com) / [fendxtech.com](https://fendxtech.com)